4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Aarti Pharmalabs Limited (AARTIPHARM) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Mumbai, India with about 2,421 employees. Its market capitalization is roughly ₹80 billion. In the fiscal year ended 2026-03-31, AARTIPHARM reported ₹17.9B in revenue and ₹1.7B in net income.
Aarti Pharmalabs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally.
Interactive charts & full statements → Open the AARTIPHARM valuation workbench →
| Income statement | TTM → 2026-06-30 | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|---|
| Total Revenue | ₹19.7B | ₹17.9B | ₹20.9B | ₹18.2B | ₹19.4B | — |
| Gross Profit | ₹10.7B | ₹7.9B | ₹8.7B | ₹7.0B | ₹6.8B | — |
| Operating Income (EBIT) | ₹3.3B | ₹3.0B | ₹3.8B | ₹3.1B | ₹2.8B | — |
| Net Income | ₹2.1B | ₹1.7B | ₹2.7B | ₹2.2B | ₹1.9B | — |
INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|---|
| Total Revenue | ₹5.4B | ₹5.8B | ₹4.3B | ₹4.2B | ₹3.9B |
| Gross Profit | ₹3.0B | ₹3.0B | ₹2.6B | ₹2.1B | ₹2.2B |
| Operating Income (EBIT) | ₹1.0B | ₹1.0B | ₹737M | ₹500M | ₹724M |
| Net Income | ₹761M | ₹611M | ₹480M | ₹279M | ₹460M |
INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Dividends Paid | (₹363M) | (₹317M) | (₹181M) | (₹181M) | — |
INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Total Assets | ₹34.8B | ₹29.0B | ₹25.8B | ₹22.4B | — |
| Total Liabilities | ₹13.6B | ₹9.1B | ₹8.3B | ₹6.9B | — |
INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive AARTIPHARM viewer.
About TickerBase · Data methodology & sources · Privacy · Terms